Anti-IL-36R antibodies, potentially useful for the treatment of psoriasis: A patent evaluation of WO2013074569

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 4, 2014, Pages 477-479

  Wolf, Joel ^a   Ferris, Laura Korb ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Biologic therapies; IL 36R; Monoclonal antibody; Psoriasis

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 36 RECEPTOR ANTIBODY; INTERLEUKIN 36ALPHA; INTERLEUKIN 36BETA; INTERLEUKIN 36GAMMA; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; INTERLEUKIN RECEPTOR; INTERLEUKIN-36 RECEPTOR, HUMAN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CYTOKINE PRODUCTION; DRUG RECEPTOR BINDING; GENE OVEREXPRESSION; HUMAN; IMMUNOTHERAPY; NONHUMAN; PSORIASIS; PUSTULAR PSORIASIS; SIGNAL TRANSDUCTION; SKIN BIOPSY; SKIN DEFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; MOUSE; PATENT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; MICE; PATENTS AS TOPIC; PSORIASIS; RECEPTORS, INTERLEUKIN;

EID: 84896452479     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.881473     Document Type: Article

References (12)

1. Towne JE, Garka KE, Renshaw BR, et al. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem 2004;279(14):13677-88
2. Boehringer Ingelheim International GMBH. Anti IL-36R antibodies for diagnostic and therapeutic use. WO2013074569A1; 2012
3. van de Veerdonk FL, Netea MG. New insights in the immunobiology of IL-1 family members. Front Immunol 2013;4:167
4. Debets R TJ, Homey B, Zurawski S, et al. Two novel IL-1 family members, IL-1delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappaB activation through the orphan IL-1 receptor-related protein 2. J Immunol 2001;167(3):1440-6
5. Johnston A, Xing X, Guzman AM, et al. IL-1F5,-F6,-F8, and-F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol 2011;186(4):2613-22
6. Carrier Y, Ma HL, Ramon HE, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol 2011;131(12):2428-37
7. Frey S, Derer A, Messbacher ME, et al. The novel cytokine interleukin-36alpha is expressed in psoriatic and rheumatoid arthritis synovium. Ann Rheum Dis 2013;72(9):1569-74
8. Tortola L, Rosenwald E, Abel B, et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest 2012;122(11):3965-76
9. Blumberg H, Dinh H, Trueblood ES, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med 2007;204(11):2603-14
10. Blumberg H, Dinh H, Dean C Jr, et al. IL-1RL2 and its ligands contribute to the cytokine network in psoriasis. J Immunol 2010;185(7):4354-62
11. Kanazawa N, Nakamura T, Mikita N, Furukawa F. Novel IL36RN mutation in a Japanese case of early onset generalized pustular psoriasis. J Dermatol 2013;40(9):749-51
12. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011;365(7):620-8